Rocket Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Rocket Pharmaceuticals
RCKT Stock  USD 3.89  0.35  9.89%   
Analyzing historical trends in various income statement and balance sheet accounts from Rocket Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Rocket Pharmaceuticals' valuation are summarized below:
Market Capitalization
421 M
Earnings Share
(2.25)
There are currently one hundred twenty trending fundamental ratios for Rocket Pharmaceuticals that can be evaluated and compared over time across competitors. All traders should check out Rocket Pharmaceuticals' recent fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 935.4 M in 2026. Enterprise Value is likely to drop to about 853 M in 2026
Check Rocket Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rocket Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.3 M, Interest Expense of 3.2 M or Selling General Administrative of 123.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.76. Rocket financial statements analysis is a perfect complement when working with Rocket Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Rocket Stock
Check out the analysis of Rocket Pharmaceuticals Correlation against competitors.
For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.

Rocket Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets314.9 M606.9 M273.3 M
Slightly volatile
Short and Long Term Debt Total30.6 M29.3 M25.1 M
Slightly volatile
Total Current Liabilities49.1 M46.8 M20.4 M
Slightly volatile
Accounts Payable3.7 M1.9 M2.9 M
Pretty Stable
Cash117.9 M188.2 M100.1 M
Slightly volatile
Non Current Assets Total180.5 M171.9 M70.5 M
Slightly volatile
Cash And Short Term Investments240.2 M428.2 M206.5 M
Slightly volatile
Common Stock Total Equity778.8 K741.8 K374.3 K
Slightly volatile
Common Stock Shares Outstanding114.5 M109 M41.7 M
Slightly volatile
Liabilities And Stockholders Equity314.9 M606.9 M273.3 M
Slightly volatile
Non Current Liabilities Total28.6 M21.4 M33.7 M
Pretty Stable
Other Current Assets7.1 M6.7 M3 M
Slightly volatile
Other Stockholder Equity2 B1.9 B732.7 M
Slightly volatile
Total Liabilities59.9 M74.1 M53.4 M
Slightly volatile
Total Current Assets243.4 M434.9 M209.3 M
Slightly volatile
Short Term Debt2.8 M3.3 M2.2 M
Pretty Stable
Common Stock1.3 M1.2 M481 K
Slightly volatile
Other Liabilities3.1 M3 M1 M
Slightly volatile
Short and Long Term Debt2.7 M4.4 M4.5 M
Pretty Stable
Property Plant And Equipment Net100.6 M95.8 M36.9 M
Slightly volatile
Short Term Investments159 M240 M117.7 M
Slightly volatile
Capital Surpluse549.2 M1.1 B558.4 M
Slightly volatile
Property Plant And Equipment Gross126.3 M120.3 M42.8 M
Slightly volatile
Non Current Liabilities Other1.2 M1.3 M2 M
Pretty Stable
Property Plant Equipment93.8 M89.3 M32.1 M
Slightly volatile
Long Term Debt Total35.2 M31.6 M42.4 M
Slightly volatile
Net Invested Capital430.2 M532.7 M280.8 M
Slightly volatile
Net Working Capital329.6 M388.1 M223.1 M
Slightly volatile
Capital Stock787.9 K1.2 M626 K
Slightly volatile
Capital Lease Obligations22 M29.3 M11.4 M
Slightly volatile

Rocket Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization11.3 M10.8 M3.1 M
Slightly volatile
Interest Expense3.2 M2.2 M2.5 M
Slightly volatile
Selling General Administrative123.1 M117.3 M36.5 M
Slightly volatile
Other Operating Expenses329.9 M314.2 M116 M
Slightly volatile
Research Development206.8 M196.9 M79.5 M
Slightly volatile
Total Operating Expenses329.9 M314.2 M116 M
Slightly volatile
Interest Income19.7 M18.8 M5.1 M
Slightly volatile
Reconciled Depreciation11.3 M10.8 M3.2 M
Slightly volatile
Selling And Marketing Expenses1.4 M1.6 M1.7 M
Slightly volatile

Rocket Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow100.1 M65.9 M80.1 M
Slightly volatile
Depreciation11.3 M10.8 M3.1 M
Slightly volatile
Total Cash From Financing Activities114.1 M213.6 M98.9 M
Slightly volatile
End Period Cash Flow118.7 M189.7 M100.8 M
Slightly volatile
Change To Netincome25.4 M36.1 M19.9 M
Slightly volatile
Issuance Of Capital Stock203.7 M213.6 M173.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.680.728.8074
Pretty Stable
Payables Turnover5.455.193.044
Slightly volatile
Cash Per Share8.374.526.6525
Pretty Stable
Days Payables Outstanding69.1272.765 K
Slightly volatile
Income Quality0.870.930.8431
Slightly volatile
Intangibles To Total Assets0.0770.110.1083
Slightly volatile
Current Ratio10.138.3710.811
Slightly volatile
Capex Per Share0.05290.05560.124
Pretty Stable
Interest Debt Per Share0.320.331.9321
Slightly volatile
Debt To Assets0.05280.05560.5576
Slightly volatile
Days Of Payables Outstanding69.1272.765 K
Slightly volatile
Ebt Per Ebit1.341.091.1984
Pretty Stable
Quick Ratio10.138.3710.811
Slightly volatile
Net Income Per E B T1.131.141.0624
Pretty Stable
Cash Ratio7.944.636.3033
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.880.931.057
Very volatile
Debt Ratio0.05280.05560.5576
Slightly volatile

Rocket Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap935.4 M1.1 B894 M
Slightly volatile
Enterprise Value853 M948.2 M797.7 M
Slightly volatile

Rocket Fundamental Market Drivers

Rocket Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Rocket Pharmaceuticals Financial Statements

Rocket Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Rocket Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Rocket Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Rocket Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-11.5 M-10.9 M
Cost Of Revenue10.8 M11.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY